• (+)-Bicuculline: Technical Guide for GABAA Antagonist Use

  2026-05-18

  (+)-Bicuculline is a well-established GABAA receptor antagonist for dissecting inhibitory neurotransmission and synaptic NMDA receptor signaling in neuroscience research. Its value is maximized in controlled laboratory experiments requiring precise modulation of GABAergic signaling pathways. It is not appropriate for diagnostic or clinical applications.

• AICAR Phosphate (Acadesine): Advanced Workflows for B-CLL Ap

  2026-05-17

  AICAR phosphate (Acadesine) empowers targeted AMPK-driven apoptosis assays in B-cell chronic lymphocytic leukemia (B-CLL) research, enabling precise modulation of mitochondrial and caspase pathways. This guide delivers stepwise protocols, troubleshooting insights, and evidence-based innovation—bridging recent reference findings with optimized experimental design.

• BFH772 (VEGFR2 Inhibitor): Technical Use and Protocol Parame

  2026-05-16

  BFH772 is a highly selective VEGFR2 inhibitor designed for researchers studying VEGFR2-driven angiogenesis, particularly in tumor angiogenesis models. It is not suited for workflows requiring water solubility or broad-spectrum kinase inhibition due to its narrow selectivity and solubility profile.

• Biomimetic Microparticles Disrupt Tumor pH for Chemo-Immunot

  2026-05-15

  This study introduces a biomimetic microparticle system capable of simultaneously disrupting both intracellular and extracellular pH homeostasis in tumor cells by blocking lactate export and enabling pH-dependent drug activation. The approach synergizes chemotherapy and immunotherapy, offering a promising strategy for tumor suppression and immune modulation.

• 4-Ethylphenyl Sulfate (SKU B6051): Optimizing Renal and Neur

  2026-05-15

  This article addresses reproducibility and workflow challenges in cell-based, behavioral, and biomarker assays by focusing on 4-ethylphenyl sulfate (SKU B6051). Drawing on recent literature and product data, it demonstrates how this high-purity, research-grade compound from APExBIO supports sensitive, reliable, and data-backed experimental outcomes in gut-brain and renal research.

• Copper-Coordinated Nanoassemblies for Multimodal Cancer Ther

  2026-05-14

  This study presents a baicalein–copper nanoassembly (BCB) integrating chemodynamic and photodynamic therapy for enhanced tumor ablation, with bone-penetrating and cuproptosis-inducing capabilities. The platform demonstrates potent ROS generation, glutathione depletion, and selective tumor targeting, offering a promising strategy for treating primary and metastatic cancers.

• GM 6001 (Galardin): Optimizing MMP Inhibition in ECM Researc

  2026-05-14

  GM 6001 (Galardin) empowers researchers with precise, broad-spectrum matrix metalloproteinase inhibition across tissue engineering, cancer biology, and vascular models. This article delivers actionable workflows, troubleshooting tips, and evidence-driven protocol enhancements to maximize assay reproducibility and data clarity.

• Z-YVAD-FMK: Caspase-1 Inhibitor for Pyroptosis & Apoptosis A

  2026-05-13

  Z-YVAD-FMK empowers precise dissection of inflammatory cell death and cytokine signaling in cancer and immune models. This guide delivers protocol-ready insights, literature-grounded troubleshooting, and cross-study applications for robust apoptosis and pyroptosis research.

• Transmission Dynamics of Carbapenemase Genes in CREC (2022–2

  2026-05-13

  This study systematically characterizes the prevalence and transferability of carbapenemase-encoding genes (CEGs) in carbapenem-resistant Enterobacter cloacae (CREC) isolates from eight teaching hospitals in Guangdong, China (2022–2024). The research highlights the predominance of plasmid-borne blaNDM-1, high rates of multidrug resistance, and robust horizontal gene transfer, informing surveillance and resistance management strategies.

• 2,5-di-tert-butylbenzene-1,4-diol (BHQ): Redefining SERCA In

  2026-05-12

  Explore how 2,5-di-tert-butylbenzene-1,4-diol (BHQ) is transforming calcium signaling research and hematopoietic stem cell mobilization through selective SERCA inhibition. This article delivers unique, evidence-based insights for optimizing experimental design in stem cell and vascular studies.

• Targeted mRNA Nanoparticles Restore BBB After Ischemic Strok

  2026-05-12

  This study demonstrates a lipid nanoparticle system for targeted delivery of IL-10 mRNA to ischemic brain regions, effectively modulating microglia polarization and repairing the blood–brain barrier after stroke. The work highlights a positive feedback loop between therapeutic mRNA delivery and microglial phenotype switching, opening new avenues for mRNA-based neuroprotection.

• Rewriting RNA Therapeutics: Translational Leverage with Hype

  2026-05-11

  This thought-leadership article explores the mechanistic underpinnings and translational strategies that drive next-generation RNA-based therapies, focusing on the pivotal role of the HyperScribe™ T7 High Yield RNA Synthesis Kit. Integrating cutting-edge findings on pseudouridine's immunomodulatory role in mRNA, the piece offers actionable protocol guidance and strategic foresight for researchers navigating the fast-evolving landscape of RNA synthesis, vaccine design, and functional genomics.

• Valemetostat (DS-3201): Precision EZH2 Inhibition in Lymphom

  2026-05-11

  Valemetostat empowers researchers with dual EZH1/2 inhibition, enabling reproducible epigenetic cancer therapy studies in lymphoma models. This guide details optimized workflows, protocol enhancements, and troubleshooting grounded in translational evidence.

• PF-562271 HCl: Optimizing FAK/Pyk2 Inhibition in Cancer Rese

  2026-05-10

  PF-562271 HCl sets a new benchmark for reliable, nanomolar-precision FAK/Pyk2 inhibition in cancer biology workflows. This guide translates advanced research and practical scenarios into actionable insights, enabling reproducible results in tumor growth, metastasis, and microenvironment studies.

• Uremic Toxins and PEO Chain Density: Impacts on Protein Adso

  2026-05-09

  This study investigates how uremic toxins, including 4-ethylphenyl sulfate, alter plasma protein adsorption on methoxy-PEO (mPEO) modified surfaces, with direct implications for blood-contacting biomaterial design in chronic kidney disease. The findings emphasize the need to consider disease-specific blood chemistry, particularly toxin accumulation, when developing and testing hemocompatible materials.

452 records 18/31 page Previous Next First page 上5页 1617181920 下5页 Last page